UMIN-CTR Clinical Trial

Basic information
Public title	Analysis on individual difference in pharmacokinetics of aprepitant and its metabolites, and investigation on predictive parameters of aprepitant response and adverse effects in Japanese patiens
Acronym	Analysis on individual difference in pharmacokinetics of aprepitant and its metabolites, and investigation on predictive parameters of aprepitant response and adverse effects in Japanese patiens
Scientific Title	Analysis on individual difference in pharmacokinetics of aprepitant and its metabolites, and investigation on predictive parameters of aprepitant response and adverse effects in Japanese patiens
Scientific Title:Acronym	Analysis on individual difference in pharmacokinetics of aprepitant and its metabolites, and investigation on predictive parameters of aprepitant response and adverse effects in Japanese patiens
Region	Japan

Condition
Condition	head and neck cancer
Classification by specialty	Oto-rhino-laryngology
Classification by malignancy	Malignancy
Genomic information	YES

Objectives
Narrative objectives1	This study evaluate the interindividual variabilities of plasma dispositions of aprepitant and its metabolites determined by LC-MS/MS and clinical responses and adverse effects by investigating the patient background, plasma concentrations of proteins related with aprepitant metabolism, and genetic variants of cytochrome P450.
Basic objectives2	PK,PD
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes	Plasma concentrations of aprepitant and its metabolites at 24 hours after the last oral administration of aprepitant.
Key secondary outcomes

Base
Study type	Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit	Not applicable
Age-upper limit	Not applicable
Gender	Male and Female
Key inclusion criteria	1. Patients treated with aprepitant for chemotherapy induced nausea and vomiting 2. Patients receiving written informed consent
Key exclusion criteria	1. Patients discontinuing aprepitant 2. Patients who are judged by physicians as inappropriate for study enrollment
Target sample size	150

Research contact person
Name of lead principal investigator	1st name Junichi Middle name Last name Kawakami
Organization	Hamamatsu University School of Medicine
Division name	Department of Hospital pharmacy
Zip code	4313192
Address	1-20-1 Handayama, Hamamatsu 431-3192
TEL	053-435-2763
Email	pharmacyham-adm@umin.ac.jp

Public contact
Name of contact person	1st name Takafumi Middle name Last name Naito
Organization	Hamamatsu University School of Medicine
Division name	Department of Hospital pharmacy
Zip code	4313192
Address	1-20-1 Handayama, Hamamatsu 431-3192
TEL	053-435-2763
Homepage URL
Email	pharmacyham-adm@umin.ac.jp

Sponsor
Institute	Department of Hospital pharmacy Amaterasu University School of Medicine
Institute
Department

Funding Source
Organization	Department of Hospital pharmacy Amaterasu University School of Medicine
Organization
Division
Category of Funding Organization	Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization	Hamamatsu University School of Medicine
Address	1-20-1 Handayama, Hamamatsu 431-3192
Tel	053-435-2111
Email	rinri@hama-med.ac.jp

Secondary IDs
Secondary IDs	NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information	2020 Year 07 Month 13 Day

Related information
URL releasing protocol
Publication of results	Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status	Enrolling by invitation
Date of protocol fixation	2017 Year 07 Month 14 Day
Date of IRB	2017 Year 08 Month 04 Day
Anticipated trial start date	2017 Year 08 Month 04 Day
Last follow-up date	2022 Year 07 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other

Other related information

Study design: Observational study Object recruitment: All patients who visit our hospital and meet the selection criteria from August 2017 to July 2022 Primary outcome: Plasma concentrations of aprepitant and its metabolites at 24 hours after the last oral administration of aprepitant. Antiemetic effects and adverse effects Secondary outcome: 1. Plasma 4beta-hydroxycholesterol 2. Plasma miRNA-27b 3. Plasma 25-hydroxy vitamin D 4. Polymorphisms of CYP3A4 and CYP3A5 5. Blood inflammation marker levels 6. Concomitant regimen, type of anticancer drug, and dosage 7. Hyperglycemia-related markers (1,5-AG, C-peptide, glycoalbumin etc.) 8. Patient background data(sex, age, weight etc.) 9. Laboratory values 10. Concomitant drugs

Management information
Registered date	2020 Year 07 Month 10 Day
Last modified on	2020 Year 07 Month 10 Day

Link to view the page
URL(English)	https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046868